# Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

> **NCT02758171** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT02758171
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-17
- **Primary completion:** 2016-07-29
- **Final completion:** 2016-08-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02758171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02758171, "Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02758171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*